Literature DB >> 9672852

Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity.

P M Flood1, X Liu, R Alexander, H Schreiber, S Haque.   

Abstract

A number of ultraviolet light-induced tumors that do not grow progressively in 3- or 9-month-old animals grow progressively in animals starting at approximately 15 months of age. We investigated the immune response to one such tumor, 6130, in young and old mice to determine in nature of this breakdown in immune protection with age. The 6130 tumor cells that grow progressively in 22-month-old animals still retain sensitivity of cytotoxic T lymphocytes (CTLs) generated against the highly immunogenic "6130-A" antigen and consequently are still immunologically rejected when transplanted into 3- and 9-month-old animals, but not in mice older than 15 months. Investigation of the CD8+ CTL response found that in animals 3-12 months old, primary and secondary tumor-specific CTL responses to 6130 can be generated in vivo and in vitro. On the other hand, the CD8+ CTL responses to 6130 seen in animals 15 months of age or older were significantly depressed or absent. These results indicate that a decline in antigen-specific CD8+ CTL is the major cause of increased susceptibility to 6130 tumor growth in older animals.

Entities:  

Mesh:

Year:  1998        PMID: 9672852     DOI: 10.1097/00002371-199807000-00008

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  5 in total

Review 1.  Adapting Cancer Immunotherapy Models for the Real World.

Authors:  Lauryn E Klevorn; Ryan M Teague
Journal:  Trends Immunol       Date:  2016-04-19       Impact factor: 16.687

2.  Long-term immunological memory in the resistance of rats to transplanted intracerebral 9L gliosarcoma (9LGS) following subcutaneous immunization with 9LGS cells.

Authors:  H M Smilowitz; D D Joel; D N Slatkin; P L Micca; M M Nawrocky; K Youngs; W Tu; J A Coderre
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

3.  Induction of tolerance to immunogenic tumor antigens associated with lymphomagenesis in HOX11 transgenic mice.

Authors:  S Rosic-Kablar; K Chan; M D Reis; I D Dubé; M R Hough
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 4.  Optimization of immunotherapy in elderly cancer patients.

Authors:  Kei Tomihara; Tyler J Curiel; Bin Zhang
Journal:  Crit Rev Oncog       Date:  2013

5.  Development of effective vaccines for old mice in a tumor model.

Authors:  David N Posnett; Manuel E Engelhorn; Yun Lin; Taha Merghoub; Fei Duan; Jedd D Wolchok; Alan N Houghton
Journal:  Vaccine       Date:  2008-12-25       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.